

Ref. No: 465120122
From: Commercial
Date: 12/01/22
Subject: Rheumatology

REQUEST

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

RESPONSE

Pharmacy Response

<u>Drug Name</u>	<u>Number of Patients</u>
Abatacept [Orencia]	29
Adalimumab [Humira]	40
Adalimumab Biosimilars	130
Apremilast [Otezla]	* <5
Baricitinib [Olmiant]	54
Certolizumab [Cimzia]	16
Etanercept [Enbrel]	42
Etanercept Biosimilars	98
Filgotinib [Jyseleca]	* <5
Golimumab [Simponi]	34
Guselkumab [Tremfya]	0
Infliximab [Remicade]	* <5
Infliximab Biosimilars	12
Ixekizumab [Taltz]	0
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	0
Rituximab Biosimilars	0
Sarilumab [Kevzara]	0
Secukinumab [Cosentyx]	24
Tocilizumab [Ro Actemra]	41
Tofacitinib [Xeljanz]	25
Upadacitinib [Rinvoq]	0
Ustekinumab [Stelara]	* <5

Please note * <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients can not be identified.